Ovarian Cancer Claim For Antisoma Oncologic On Back Burner
This article was originally published in The Pink Sheet Daily
Executive Summary
Disappointing Phase II results for ASA404, which is licensed to Novartis, will not impact research in lung, prostate cancer.
You may also be interested in...
Novartis Launches Phase III Trial For NSCLC Candidate
Called a potential blockbuster by Novartis, ASA404 will be tested in 1,200 patients to measure overall survival.
Novartis Launches Phase III Trial For NSCLC Candidate
Called a potential blockbuster by Novartis, ASA404 will be tested in 1,200 patients to measure overall survival.
Oxigene Reports Positive Data For Zybrestat In Platinum-Resistant Ovarian Cancer
Novel vascular disrupting agent is also in studies for anaplastic thyroid cancer and macular degeneration.